Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › doxorubicin

doxorubicin

17 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of doxorubicin

275 trials tracked of doxorubicin: 74 in phase 3 or 4 and 50 with published results. The most-cited published study has 2781 citations.

275Trials tracked
74Phase 3 & 4
0Recruiting
50With published results
Phase distribution
Phase 4 3 Phase 3 71 Phase 2 176 Phase 1 17 Other / NA 8
  1. Phase 3 Combination Chemotherapy With or Without Trastuzumab in Treating Women With Breast Cancer Completed · 2,781 cited
  2. Phase 3 A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer Completed · 1,062 cited
  3. Phase 3 Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) Completed · 868 cited
  4. Phase 3 ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas Completed · 728 cited
  5. Phase 3 A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma Completed · 618 cited
  6. Phase 3 Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Completed · 545 cited
Show 44 more trials
  1. Phase 3 Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Completed · 427 cited
  2. Phase 3 Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Completed · 421 cited
  3. Phase 3 Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma Completed · 363 cited
  4. Phase 3 Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer Completed · 343 cited
  5. Phase 3 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma Completed · 341 cited
  6. Phase 3 A Frontline Therapy Trial in Participants With Advanced Classical Hodgkin Lymphoma Completed · 330 cited
  7. Phase 3 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Completed · 303 cited
  8. Phase 3 Efficacy and Safety Study of Lenalidomide Plus R-CHOP Chemotherapy Versus Placebo Plus R-CHOP Chemotherapy in Untreated ABC Type Diffuse Large B-cell Lymphoma Completed · 270 cited
  9. Phase 3 05-001: Treatment of Acute Lymphoblastic Leukemia in Children Completed · 241 cited
  10. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Completed · 231 cited
  11. Phase 3 Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment Completed · 208 cited
  12. Phase 3 Four Versus Six Cycles of Cyclophosphamide/Doxorubicin or Paclitaxel in Adjuvant Breast Cancer Completed · 205 cited
  13. Phase 3 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed · 176 cited
  14. Phase 3 A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer Completed · 167 cited
  15. Phase 3 Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) Completed · 150 cited
  16. Phase 3 Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast Cancer Completed · 144 cited
  17. Phase 3 Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor Completed · 133 cited
  18. Phase 3 Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma Completed · 129 cited
  19. Phase 3 Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Completed · 120 cited
  20. Phase 3 Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor Completed · 119 cited
  21. Phase 3 A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer Completed · 114 cited
  22. Phase 3 Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma Completed · 102 cited
  23. Phase 3 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Completed · 100 cited
  24. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations Completed · 86 cited
  25. Phase 3 A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer Completed · 64 cited
  26. Phase 3 Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma Completed · 59 cited
  27. Phase 3 FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients Completed · 57 cited
  28. Phase 3 Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia Completed · 48 cited
  29. Phase 3 Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia Completed · 47 cited
  30. Phase 3 Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma Completed · 42 cited
  31. Phase 3 A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM) Completed · 32 cited
  32. Phase 3 Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease Completed · 32 cited
  33. Phase 3 A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer Completed · 31 cited
  34. Phase 3 A Study of PCI-32765 (Ibrutinib) in Combination With Either Bendamustine and Rituximab or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Participants With Previously Treated Indolent Non-Hodgkin Lymphoma Completed · 27 cited
  35. Phase 3 A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer Completed · 27 cited
  36. Phase 3 TAC Versus TC for Adjuvant Breast Cancer Completed · 23 cited
  37. Phase 3 Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor Completed · 21 cited
  38. Phase 3 Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma Completed · 19 cited
  39. Phase 3 Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma Completed · 19 cited
  40. Phase 3 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Completed · 16 cited
  41. Phase 3 Rituximab and Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With B-Cell Non-Hodgkin's Lymphoma Completed · 16 cited
  42. Phase 3 A Study of the Safety of Subcutaneously Administered Trastuzumab (Herceptin) in Participants With Early and Locally Advanced Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Completed · 12 cited
  43. Phase 3 Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Completed · 10 cited
  44. Phase 4 Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide Completed

Showing the 50 most-cited and recently-updated of 275 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Ferroptosis regulation via phytochemicals and targeted delivery systems offers potential to mitigate doxorubicin-induced cardiotoxicity
Cardiology Sys. Review
Ferroptosis regulation via phytochemicals and targeted delivery systems offers potential to mitigate doxorubicin-induced cardiotoxicity New strategies may protect heart during chemo without reducing cancer fight
This systematic review examines the mechanisms of myocardial ferroptosis during doxorubicin treatment and evaluates various intervention str…
A review reveals innovative ways to shield the heart from doxorubicin damage while keeping its cancer-killing power intact.
Frontiers Jul 26, 2026
Doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy significantly suppresses tumor volume in breast cancer xenograft models
Oncology Meta-analysis
Doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy significantly suppresses tumor volume in breast cancer xenograft models Combining graphene and light shows promise for breast cancer
This meta-analysis of preclinical studies evaluates doxorubicin-loaded graphene nanoplatform chemo-photothermal therapy (CPT) compared to ph…
A new method combining a graphene platform with heat therapy may shrink breast cancer tumors more effectively than using heat alone.
Jul 17, 2026
Pola-R-CHP reduces progression risk 35% in double-expressor DLBCL, but OS unchanged
Allergy & Immunology Meta-analysis
Pola-R-CHP reduces progression risk 35% in double-expressor DLBCL, but OS unchanged New Treatment Options Show Promise for Specific Lymphoma Patients
This network meta-analysis of 1,016 treatment-naïve patients with MYC/BCL2 double-expressor DLBCL found that Pola-R-CHP significantly reduce…
A new drug combination may reduce the risk of disease progression in patients with a specific type of lymphoma.
Frontiers Jun 23, 2026
Tafasitamab plus lenalidomide and R-CHOP improves progression-free survival in high-risk DLBCL
Oncology RCT
Tafasitamab plus lenalidomide and R-CHOP improves progression-free survival in high-risk DLBCL Trial shows new treatment improves progression-free survival for lymphoma
This Phase 3 randomized, double-blind, placebo-controlled trial evaluated tafasitamab plus lenalidomide and R-CHOP in patients with high-ris…
A new drug combination showed improved progression-free survival for patients with high-risk large B-cell lymphoma in a Phase 3 clinical tri…
Jun 20, 2026
Pleuropulmonary blastoma diagnosed after initial rhabdomyosarcoma interpretation in a 2-year-old boy
Pediatrics Sys. Review
Pleuropulmonary blastoma diagnosed after initial rhabdomyosarcoma interpretation in a 2-year-old boy Case report shows rare lung cancer in toddler with DICER1
This case report describes a 2-year-old boy with a thoracic mass initially interpreted as embryonal rhabdomyosarcoma, later diagnosed as ple…
A toddler’s lung tumor was reclassified as a rare cancer linked to DICER1 syndrome, changing his treatment and highlighting a key diagnosis …
Frontiers Jun 5, 2026
TAC chemotherapy improves relapse-free survival in certain early breast cancer subtypes
OB/GYN & Women's Health RCT
TAC chemotherapy improves relapse-free survival in certain early breast cancer subtypes Doctors found that certain tumor markers might help choose the best cancer treatment plan for some patients
A randomized trial compared TAC to ddAC in early breast cancer. The authors observed improved relapse-free survival in specific tumor subtyp…
This study looked at how two different drug schedules worked for people with early breast cancer. Results suggest that specific tumor featur…
Jun 1, 2026
Case report of 3-year-old girl with bilateral Wilms tumor and TP53 mutation treated with VAD chemotherapy and surgery
Pulmonology & Critical Care Sys. Review
Case report of 3-year-old girl with bilateral Wilms tumor and TP53 mutation treated with VAD chemotherapy and surgery 3-year-old girl with TP53 mutation and bilateral Wilms tumor died after treatment
This case-based review describes a single 3-year-old girl with bilateral Wilms tumor and a TP53 mutation treated under the Chinese Children …
A single case report describes a 3-year-old girl with bilateral Wilms tumor and a TP53 mutation who died despite aggressive chemotherapy and…
Frontiers May 22, 2026
Meta-analysis of double-expressor lymphoma prognoses and novel therapies
Infectious Disease Meta-analysis
Meta-analysis of double-expressor lymphoma prognoses and novel therapies Double-expressor lymphoma linked to worse survival outcomes in large study
This systematic evaluation meta-analysis of 9,808 patients with diffuse large B-cell lymphoma found double-expressor lymphoma (DEL) is assoc…
A major review finds double-expressor lymphoma patients have worse survival. New drug combinations show promise for better results.
Frontiers May 22, 2026
Systematic review and meta-analysis of DDS-based chemotherapy in murine colon cancer models
Oncology Meta-analysis
Systematic review and meta-analysis of DDS-based chemotherapy in murine colon cancer models Targeted drug delivery shrinks colon cancer tumors in mice by over half
This systematic review and meta-analysis evaluates DDS-based chemotherapy in murine models of colon cancer. The analysis pooled data from 53…
A new analysis of mouse studies shows targeted drug delivery systems significantly reduce colon cancer tumor growth compared to standard tre…
May 20, 2026
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL
Oncology RCT
Tucidinostat plus R-CHOP improves outcomes in MYC/BCL2 double-expressor DLBCL New drug tucidinostat improves outcomes for high-risk lymphoma patients
A phase 3 trial found adding oral tucidinostat to R-CHOP significantly improved event-free survival and complete response rates in patients …
A large trial shows adding tucidinostat to standard chemo lowers disease risk and improves survival for patients with aggressive lymphoma.
JAMA May 19, 2026
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma
Oncology RCT
Ibrutinib plus chemo without ASCT shows survival benefit in mantle cell lymphoma Adding stem cell transplant to ibrutinib treatment offered no extra benefit for lymphoma patients
In younger patients with mantle cell lymphoma, adding ASCT to an ibrutinib regimen did not improve outcomes but increased toxicity. Ibrutini…
Adding stem cell transplant to ibrutinib did not improve survival for younger lymphoma patients but increased side effects.
May 16, 2026
UK trial reports 4-year event-free survival of 63% and overall survival of 68% in relapsed Wilms tumour patients
Pediatrics
UK trial reports 4-year event-free survival of 63% and overall survival of 68% in relapsed Wilms tumour patients High-dose chemo plus stem cell rescue offers hope for relapsed Wilms tumour
This clinical trial report evaluates outcomes for 78 children with relapsed or refractory Wilms tumour treated in the United Kingdom.
A UK trial found that a risk-stratified protocol with high-dose melphalan and stem cell rescue helped some children with relapsed Wilms tumo…
May 1, 2026

All doxorubicin Articles